MedPath

Het effect van fenretinide op insulinegevoeligheid.

Recruiting
Conditions
ObesityMetabolic syndrome XInsulin resistanceFatty liver
Registration Number
NL-OMON25232
Lead Sponsor
Academic Medical Center (AMC)
Brief Summary

/A

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Not specified
Target Recruitment
20
Inclusion Criteria

1. Post menopausal female;

2. Age 40-65 years;

Exclusion Criteria

1. T2DM treated with medication other than metformin or sulfonylurea derivates;

2. Any medical condition except for glucose intolerance, T2DM, hypertension and secondary dyslipidemia;

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Changes in hepatic and peripheral insulin sensitivity.
Secondary Outcome Measures
NameTimeMethod
1. Liver steatosis;<br /><br>2. Plasma retinol and RBP4 levels;<br /><br>3. Subcutaneous adipose tissue: Concentrations of RBP4 and key proteins involved in insulin signaling levels;<br /><br>4. Plasma HPR and its metabolites (MPR, 4-oxo-HPR) levels;<br /><br>5. Resting energy expenditure (REE) and body fat composition;<br /><br>6. Glucoregulatory hormones, adipokines and markers of inflammation;<br /><br>7. Safety and tolerability of HPR/LXS.
© Copyright 2025. All Rights Reserved by MedPath